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Interleukin-6 (IL-6) is a unique cytokine that can play both pro- and anti-inflammatory roles depending on the anatomical site
and conditions under which it has been induced. Specific neurons of the hypothalamus provide important signals to control food
intake and energy expenditure. In individuals with obesity, a microglia-dependent inflammatory response damages the neural
circuits responsible for maintaining whole-body energy homeostasis, resulting in a positive energy balance. However, little is
known about the role of IL-6 in the regulation of hypothalamic microglia. In this systematic review, we asked what types of
conditions and stimuli could modulate microglial IL-6 expression in murine model. We searched the PubMed andWeb of Science
databases and analyzed 13 articles that evaluated diverse contexts and study models focused on IL-6 expression and microglia
activation, including the effects of stress, hypoxia, infection, neonatal overfeeding and nicotine exposure, lipopolysaccharide
stimulus, hormones, exercise protocols, and aging.The results presented in this review emphasized the role of “injury-like” stimuli,
under which IL-6 acts as a proinflammatory cytokine, concomitant with marked microglial activation, which drive hypothalamic
neuroinflammation. Emerging evidence indicates an important correlation of basal IL-6 levels and microglial function with the
maintenance of hypothalamic homeostasis. Advances in our understanding of these different contexts will lead to the development
of more specific pharmacological approaches for the management of acute and chronic conditions, like obesity and metabolic
diseases, without disturbing the homeostatic functions of IL-6 and microglia in the hypothalamus.
1. Introduction
The identification of leptin uncovered the important role of
the brain in the regulation of whole-body energy homeostasis
[1], which has had a tremendous impact on our under-
standing of the underlying physiopathology of obesity and
a number of related metabolic diseases [2–4]. The hypotha-
lamus, in particular, plays an important role in metabolic
regulation, and studies have demonstrated its critical role in
the regulation of energy balance by integrating peripheral
hormone and neuronal signals of satiety and nutritional
status, as well as by directly sensing nutrients [5–8].
The leptin-melanocortin pathway is considered the most
robust regulator of whole-body energy homeostasis [9, 10].
This function is provided by two counteracting populations of
neurons in the arcuate nucleus of the hypothalamus (ARC),
the first of which is proopiomelanocortin (POMC), which has
an anorexigenic role, and the second is agouti-related peptide
(AgRP)/neuropeptide Y (NPY), which has orexigenic action
[3, 11]. These neuronal populations are sensitive to afferent
inputs, like leptin and insulin, which regulate both acute and
long-term energetic states.
Studies of diet-induced obesity (DIO) and aging have
shown that the hypothalamus is targeted by an inflammatory
process that leads to defective regulation of energy homeosta-
sis [12–15]. By activating signal transduction through toll-like
receptor 4 (TLR4), long-chain saturated fatty acids (SFAs)
induce an inflammatory response in the hypothalamus [16].
Signaling through JNK and NF-kB not only increases the
mRNA levels of TNF-𝛼, interleukin- (IL-) 1𝛽, IL-6, and IFN-𝛾
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cytokines, but can also lead to endoplasmic reticulum stress,
autophagy, and mitochondrial dysfunction [13, 17, 18].
Among the cytokines identified in the hypothalamus,
IL-6 has gained considerable attention in studies related
to metabolism due to its pleiotropic actions, not only in
the pathogenesis of inflammatory disorders, but also in the
physiological homeostasis of nervous tissue [19]. IL-6 can
stimulate responses in a given target cell in two different
ways. The classical signaling pathway corresponds to the
binding of IL-6 to its membrane-bound 𝛼-receptor, IL-6R,
resulting in dimerization of its 𝛽-receptor gp130. Alterna-
tively, transsignaling is activated when IL-6 binds to the
soluble IL-6R fraction, and this complex can then stimulate
distant cells that express gp130 but not surface-bound IL-6R
[20, 21]. Both pathways lead to the activation of downstream
JAK/STAT signaling, which upregulates the transcription
of proinflammatory genes [22, 23]. Although IL-6 levels in
the brain are low under physiological conditions, its levels
have been reported to be increased in several neurological
disorders, predominantly due to neuronal and glial cells [24].
Microglial cells are the resident macrophages of the
central nervous system (CNS) and are widely distributed
throughout the brain. They originated from primitive
macrophages in the yolk sac and form a population that is
distinct from bone marrow-derived macrophages (BMDM)
[25, 26]. Under normal physiological conditions, they are
relatively quiescent; however, after being exposed to injury or
infection stimuli, they undergomorphological and functional
changes [26]. Many mechanisms by which microglia can be
activated have been described [27, 28]. In the mediobasal
hypothalamus (MBH), glial cells, which also include astro-
cytes, have been implicated in initiating and propagating an
inflammatory process resulting in gliosis [29, 30]. Gliosis is
characterized by an increased number of glial cells, hypertro-
phy of the cell bodies and processes, and other physiological
changes. It occurs, in part, because microglial cells are
able to sense changes in the surrounding environment and
can quickly become activated to either a proinflammatory
(M1) or anti-inflammatory (M2) phenotype.When activated,
microglia release cytokines, including IL-6, in addition to
other chemokines and growth factors, in order to mitigate or
prevent damage to the brain due to the insult.
Although there has been significant progress in studies
involving glial cells and cytokines, especially in areas of
the brain that are important for metabolic physiologic con-
trol or neurodegenerative diseases, the relationship between
microglia and IL-6 in the brain remains unclear. In this
review, we searched for studies that evaluated IL-6 from a
microglial origin in the hypothalamic environment. Data
from articles were systematically reviewed to identify the
hypothalamic microglia status (whether activated and/or the
source of IL-6) and IL-6 expression (whether increased,
unaltered, or decreased) in multiple conditions related to
inflammatory/pathological processes.
PICOS Strategy. Participants: murine model. Interventions:
conditions related to inflammatory and pathological pro-
cesses. Comparisons: Hypothalamic microglia status. Out-
comes: IL-6 expression. Study design: Experimental studies.
2. Materials and Methods
2.1. Search Strategy. A systematic search was performed
in PubMed and Web of Science databases on Decem-
ber 18, 2018, for published studies on the association
between IL-6 and microglia in the hypothalamus, with no
restrictions with regard to language, timespan, or docu-
ment type, using mixed strategy keywords. The Systematic
Review Protocol was registered in “International Prospec-
tive Register of Systematic Reviews” (PROSPERO) through
the code CRD42019129248. The following search strate-
gies were used: PubMed, ((“Hypothalamus”[Mesh]) AND
“Interleukin-6”[Mesh]) AND “Microglia”[Mesh]; Web of
Science, ALL FIELDS: (“interleukin 6” and “microglia”
and “hypothalamus”). This review follows the “Preferred
Reporting Items for Systematic Reviews and Meta-Analyses”
(PRISMA) checklist (See PRISMA Checklist, Table S1).
After obtaining the search results, duplicate articles, those
that exclusively used an in vitro approach, studies without
data on IL-6 levels, and those without information regarding
microglia in the hypothalamus were identified and excluded
from this review (See Table of included and excluded articles,
Table S2).
2.2. Data Extraction and Classification. The following data
were extracted from each study: subject of study, model
adopted (in vivo and in vitro) and intervention (treatment
or exposure performed), methods of analysis (mRNA expres-
sion and protein expression), IL-6 expression and microglia
status (increased/decreased or activated/suppressed in com-
parison to control) with tissue/location, expression of IL-6
by microglia, and phenotypic outcome. When available, the
significance level (p-value) was collected. The evaluation of
risk of bias was performed using the SYRCLE’s risk of bias
tool (See Evaluation of Risk of Bias, using SYRCLE’s risk of bias
tool, Table S3), developed for animal studies.
3. Results
The search strategy identified a total of 25 articles (PubMed,
n = 13; Web of Science, n = 13, of which 12 were unique).
Twelve papers were excluded based on their title and abstract.
The remaining 13 studies were retrieved for a full evaluation
and were confirmed to fulfill the inclusion criteria (See Flow
diagram of Systematic Review provided by PRISMA, Figure
S1). Details of these 13 studies are summarized in Table 1.
3.1. Increased Hypothalamic IL-6 Expression and Microglial
Status. In this review, the publication search returned eight
articles that reported increased IL-6 expression. In five of
these articles, increased hypothalamic levels of IL-6 with
microglia activation were described. These events were
found after (a) exposure to amylin, which is synthesized
by pancreatic 𝛽-cells and is coreleased with insulin in
response to food intake and increased glucose concentrations
[31]; (b) lung coinfection, which induces neuroinflamma-
tory events, in part through serum amyloid A production
[32]; (c) lipopolysaccharide (LPS) exposure in neonatally
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overfed adults [33] and in glial cells from P2X7R-knockout
mice (purinoceptor expressed predominantly by cells with
immune origin) [34]; and (d) neonatal overfeeding itself [35].
One study showed an increase in hypothalamic IL-6
expression in the context of microglial suppression. Induced
hypoxia leads to an increase in IL-6 levels, even with sup-
pression of microglial activity in the CNS (pharmacological
suppression). Thus, the increased IL-6 expression was prob-
ably from other cell types, like astrocytes. Altered microglial
activation was related to alterations in the brain autonomic
nuclei responsible for cardiorespiratory control, leading to
impairments in breathing [36].
Finally, three studies showed increased hypothalamic
IL-6 expression but did not measure microglial activation.
Similar to amylin [31], another hormone known as mimecan
(also known as osteoglycin) can lead to an increase in
hypothalamic IL-6 expression. Using in vitro approaches,
this study showed that IL-6 is produced by microglia after
mimecan stimulus. Mimecan is expressed in adipose tissue,
and its action is related to the inhibition of food intake
and reduction of body weight in mice [37]. The final study,
which employed a model of early-life stress, found increased
hypothalamic IL-6 expression [38].
3.2. Unaltered orDecreasedHypothalamic IL-6 Expression and
Microglial Status. The expression of IL-6 was unaltered in
three studies related to (a) aging as a physiological condition,
which leads to an increase in IL-6 levels in other brain areas,
but no significant increase was observed in the hypothalamus
[39]; (b) a model of inescapable stress, in which microglial
activation was not related to increased hypothalamic IL-6
levels [40]; and (c) nicotine exposure during lactation, which
promotes paraventricular hypothalamicmicroglial activation
related to obesity in adulthood, but with no alteration in
hypothalamic IL-6 expression [41].
Lastly, two studies showed microglial suppression with
decreased IL-6 expression. The first one demonstrated
that the stress-induced increase in hypothalamic IL-6 and
microglia activation were suppressed following benzodi-
azepine treatment, ameliorating anxiety, and social avoidance
behavior in adult mice [42]. In the same way, exercise can
ameliorate hypertension in a murine model, with a marked
decrease in IL-6 expression, followed by a reduction in
microglial activation in the hypothalamus [43].
Some risks of bias were strongly present in most of the
articles analysed, as unclear or not founded information: (a)
risk of selection bias, as randomized allocation of animals and
cages; (b) risk of performance bias, as blinding of manipula-
tors about interventions performed; (c) risk of detection bias,
as random selection of animals to assess outcomes (Table S3).
4. Discussion
In this review, we present a summary of data extracted from
studies that evaluated IL-6 in hypothalamic microglia. The
models employed in the 13 studies included in this review
were divided into those considered “injury-like” stimuli,
which can interfere with the hypothalamic–pituitary–adrenal
(HPA) axis [32, 33, 38, 42], and others leading to phenotypic
manifestations such as an increase in weight gain under a
standard diet [33, 35] or anxiety-like behavior [42].
Many signaling pathways are activated by LPS or high-fat
feeding [27]. Both LPS and SFAs from the diet are recognized
by TLR4 in microglial cells, increasing the production and
release of several inflammatory cytokines by these cells [16].
The same happens with overfeeding during lactation in
neonates, which causes long-term changes that can lead to
the development of obesity [44]. In this case, when adulthood
is reached, basal hypothalamic IL-6 levels remain elevated,
concomitant with activated hypothalamic microglia [35].
Furthermore, neonatal overfeeding beginning early in life
increases hypothalamic TLR4 expression and the number of
Iba-1 (microglia/macrophage-specific protein) positive cells,
followed by increased expression of IL-6 following LPS
challenge [33].
In addition to TLR4, microglial receptors dependent
on ATP binding are also important to trigger cytokine
production. Evidence indicates that microglial IL-6 produc-
tion is more strongly associated with the activation of P2Y
receptors [45]. A study byMingam et al. (2008) confirmed the
specificity of P2 purinoceptors to the production of cytokines,
as absence of the P2X7 receptor leads to impairment only in
IL-1𝛽production by activatedmicroglia but does not interfere
with IL-6 production after LPS stimulus [34].
Neuroinflammation driven by infections and other sys-
temic inflammatory events can be modulated by several
ligands and specific receptors. Mice submitted to viral or
bacterial lung infection drive the hepatic release of circulating
amyloids, which activate PVN microglia through binding
to formyl peptide receptor 2 (Fpr2), leading to a marked
increase in hypothalamic IL-6 expression and exacerbated
neuroinflammation [32]. Other evidence suggests that the
hypothalamic distribution of receptors with multiple ligands,
such as Fpr2, can contribute to these effects [46].
Although diverse pathways are related to microglial acti-
vation related to inflammation, different conditions, such as
hormonal stimuli, can also result in microglial activation and
increased IL-6 expression [31, 37, 47]. As shown by Ropelle
et al. (2010], physical exercise increases hypothalamic IL-6
expression, which improves insulin and leptin signaling in
the hypothalamus, leading to decreased food intake in rats
fed with a high-fat diet [48]. Two of the reviewed studies
demonstrated that IL-6 can interfere with energy balance,
inhibiting food intake or reducing body weight gain, and
that hormonal signaling is related to hypothalamic IL-6
expression through different mechanisms. Amylin stimulus
increases IL-6 in the ventromedial hypothalamus (VMH)
through binding to the microglia. Elevated IL-6 can improve
leptin signaling in neurons via the phosphorylation of STAT-
3, thereby reducing body weight gain [31]. Leptin itself can
drive this event, as IL-6 is produced bymicroglia after a leptin
stimulus through activation of microglial leptin receptor
isoforms [47]. Furthermore, IL-6 can interact with leptin
in the parabrachial nucleus, leading to reduced food intake
[24]. On the other hand, mimecan can reduce food intake
independent of leptin signaling, and its action is related to
microglial IL-6 release in the hypothalamus [37]. Although
8 BioMed Research International
the increases in hypothalamic IL-6 are primarily associated
with inflammatory events and responses, growing evidence
suggests a relationship between IL-6 and hormones involved
in energy balance, which can occur in a leptin-dependent or
leptin-independent manner.
Beyond the regulation of energy balance, we found
several studies that reported noninflammatory outcomes of
IL-6 in the CNS. One of these studies was focused on
neuroplasticity via the PI3k-AKT pathway [49], while the
others assessed neuroprotection and repair events [19, 50],
the maintenance and control of proliferative niches close to
ventricles [51], and neurogenesis in the subventricular zone
mediated by IL-6 and other cytokines of microglial origin
[52].
One of the reviewed studies adopted an aerobic-training
protocol in spontaneously hypertensive rats presenting with
hypothalamic inflammation and found a decrease in high
mobility group box-1 (HMGB1, related to the injury-induced
inflammatory response) and CXCR4 signaling, which ame-
liorates the autonomic control of blood pressure due to a
reduction in microglia activation and hypothalamic IL-6
expression [43]. Indeed, anti-inflammatory events have been
found to be associated with physical exercise protocols and
an increase in circulating IL-6 released by themuscle [53, 54],
thus reinforcing the anti-inflammatory effect of exercise and
its central outcomes.
Not every inflammatory stimulus or condition is related
to increased IL-6 expression in the hypothalamus, although
it is classically associated with microglial activation along
with IL-1𝛽 and TNF𝛼 expression. In a model of inescapable
stress, microglial activation was not found to be related to an
increase in hypothalamic IL-6 levels [40]. A similar finding
was reported for nicotine exposure during lactation, with
no relationship between long-term obesity and increased
hypothalamic IL-6 expression [41]. Finally, during the aging
process, an increase in microglial IL-6 production was
observed in the cerebellum, cortex, and hippocampus, but
not in the hypothalamus. Increased IL-6 expression in the
hypothalamus did not show an age dependence [39].
Given the complexity of homeostatic maintenance and
inflammatory events, an absence of microglial activity or IL-
6 production can lead to impaired phenotypes. Under basal
conditions, microglia ablation leads to a variety of events,
including reduced neuroblast survival within the dentate
gyrus of the hippocampus [55]. In the presence of severe
injury, such as brain ischemia, microglia have been described
as an important producer of neurotrophic factors [56] and
other proteins. In a physiological context, according to the
diversemicroglial hypothalamic signatures, it acts like a “sen-
tinel,” functioning as an environmental sensor and regulator
of hypothalamic metabolic control [28]. As demonstrated by
Silva et al. (2018), pharmacological inhibition of microglia
in the CNS combined with hypoxia leads to an increase in
IL-6 expression, probably due to a different cell type, such
as astrocytes, resulting in alterations in the brain autonomic
nuclei responsible for cardiorespiratory control [36]. Further-
more, ablation of IL-6 (knockout IL-6 mice) is related to
weight gain and disturbance in glucose homeostasis during
adulthood [57]. These knockout mice have lower neuronal
protection in the dentate gyrus. Conversely, elevated expres-
sion of hippocampal IL-6 was found to be related to better
neuronal regeneration and a better neuroprotective effect
in acute lesions [58]. Furthermore, IL-6 plays a critical
role in neuronal survival during early life development
and adulthood [59]. Thus, there is evidence that IL-6 can
exert central and peripheral functions through modulation
of metabolic events, neuroprotection, and participation in
regenerative/proliferative processes.
Given the plasticity of microglia [60] and the pleiotropy
of IL-6 [22], studies that evaluate both require specific
and accurate approaches such as conditional knockouts. In
light of this, future studies should be conducted with the
purpose of clarifying the behavior of microglia, as well as
the effect of IL-6, under different conditions. Understanding
this relationship could lead to more specific pharmacological
approaches to acute and/or chronic conditions in the future,
such as the management of obesity and metabolic diseases.
This refinement is important in order not to disturb the
homeostasis of the hypothalamic environment, as IL-6 and
microglia make a remarkable contribution under normal
physiological conditions.
5. Conclusions
Advances in our understanding of microglial IL-6 hypotha-
lamic expression and its functions are important for the
interpretation of hypothalamic responses under diverse
stimuli. Taken together, our review identified three main
contexts where microglial activity and IL-6 expression are
strongly related: (1) basal levels of hypothalamic IL-6 and
microglial function are important tomaintain environmental
homeostasis; (2) some hormones can activate microglia and
increase IL-6 expression to improve hormonal signaling
in the hypothalamus; and (3) under conditions of acute
or sustained inflammatory conditions, IL-6 expression and
microglia activation will be increased together with other
inflammatory markers such as TNF𝛼 and IL-1𝛽, generating
neuroinflammatory responses (Figure 1).
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marked increase in IL-6 and other cytokine production, microglial activation, and TLR-4 activation.
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